cigna and glp 1 coverage will stop covering GLP-1 weight-loss drugs including Wegovy Zepbound in its ​employee health plan effective July 1, according to Reuters The GLP-1 paradox: too expensive

One unexpected serious adverse reaction occurred in a NAC-treated patient caused by an erroneous iv infusion rate (1.5g-loading dose-15 min followed by 7.5 g delivered over 3h15min instead of 4 h), causing chest tightness, despite stable vital signs, which was resolved by corticosteroids and discontinuation of iv NAC

Kullanm srecinde yaplan hatalar, gda takviyelerinden beklenen faydann elde edilmesini zorlatrr

New research shows promise for Novo Nordisk's IcoSema, a combination of once-weekly insulin icodec and semaglutide currently being tested in people with type 2 diabetes

Metabolic Efficiency: Researching the blends impact on basal metabolic rate, adipose tissue oxidation, and nitrogen retention